Back to News
May 5, 2026 12:01 PM

Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses

Cellectar Biosciences, Inc. (NASDAQ:CLRB) shares are up during Tuesday’s trading session as the company announced promising results from its Phase 2b CLOVER WaM clinical trial.

Trial Data Shows High Response Rates And Durability

The positive data highlight an overall response rate of 83.6% and a median duration of response of 17.8 months, suggesting strong efficacy for its treatment in heavily pretreated patients.

The trial evaluated iopofosine I 131 in patients with relapsed or refractory (r/r) Waldenström macroglobulinemia (WM), a rare, slow-growing blood cancer where abnormal B lymphocytes in the bone marrow produce excess immunoglobulin M protein.